LILLY PROZAC SALES INCREASE 7% TO $580.7 MIL. IN THIRD QUARTER; PFIZER NORVASC SUPPLANTS PROCARDIA XL AS TOP PRODUCT WITH $899.8 MIL. YEAR-TO-DATE
Executive Summary
Lilly's Prozac showed a 7% sales increase for the third quarter, posting $580.7 mil. in worldwide sales for the three months, the company reported Oct. 17